Brief: Vincerx Pharma Announces FDA Clearance Of Ind For Phase 1B Study Of Vip152 In Chronic Lymphocytic Leukemia And Richter Syndrome
20/04/2021 13:51
April 20 (Reuters) - Vincerx Pharma Inc VINC.O :
* VINCERX PHARMA ANNOUNCES FDA CLEARANCE OF IND FOR PHASE 1B
STUDY
OF VIP152 IN CHRONIC LYMPHOCYTIC LEUKEMIA AND RICHTER SYNDROME
* VINCERX PHARMA - FIRST PATIENT IN PHASE 1B STUDY IN
MYC-DRIVEN
R/R AGGRESSIVE LYMPHOMAS AND ADVANCED SOLID TUMORS EXPECTED 2Q
2021
Source text for Eikon: ID:nGNXdR5R7
Further company coverage: VINC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vincerx Pharma
See all newsBrief: Vincerx Pharma Announces Intent To Delist From Nasdaq And Deregister With The SEC
Brief: Vincerx Pharma Announces Termination Of Letter Of Intent And Board Authorization To Pursue Wind-Down Activities
Vincerx Pharma Inc reports results for the quarter ended December 31 - Earnings Summary
Vincerx Pharma Inc expected to post a loss of $3.40 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Aditxt, Natgas companies, DocuSign